Protagonist Therapeutics vs Arcus Biosciences
Arcus Biosciences reported revenue of $247 million in fiscal 2025, 5.4 times Protagonist Therapeutics' $46 million in fiscal 2025. Protagonist Therapeutics' revenue fell 89.4% in its latest year, and Arcus Biosciences' fell 4.3%. Protagonist Therapeutics had an operating margin of -343.6%, against -156.3% at Arcus Biosciences. Free cash flow was $56 million at Protagonist Therapeutics and −$484 million at Arcus Biosciences.
Side by side
| Protagonist Therapeutics | Arcus Biosciences | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $46M | $247M |
| Revenue growth | −89.4% | −4.3% |
| Revenue growth a year, last 5 years | 10.0% | 25.9% |
| Gross margin | — | — |
| Operating margin | −343.6% | −156.3% |
| Net margin | −282.8% | −142.9% |
| Free cash flow | $56M | −$484M |
| Free cash flow margin | 121.9% | −195.9% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | −2.3% | 19.2% |
| Last close | $132.04 | $18.28 |
| P/E at the last close | 28.0× | — |
| Insider trades, last 12 months | sold $79.4 million | sold $11.0 million |
| Piotroski F-score | — | 0 of 8 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Protagonist TherapeuticsArcus Biosciences
Operating margin
Percent of revenue
Protagonist TherapeuticsArcus Biosciences
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Protagonist TherapeuticsArcus Biosciences
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Protagonist Therapeutics and Arcus Biosciences pages.